Log In
Print this Print this

Exenatide once monthly

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionOnce-monthly injectable suspension formulation of synthetic exendin-4
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerAlkermes plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today